Decheng Capital China Life Sciences USD Fund III, L.P.

CIK 0001736814

1 SPAC with a current declared position, filed between Sep 10, 2024 and Sep 10, 2024. 0 of them were re-affirmed in the last 12 months. The rest are the filer’s last word on a position, not proof it is still held: an amendment is only required on a material change, so a fund that sells below 5% may never file again.

This filer has not filed a Schedule 13 on any SPAC since Sep 10, 2024. Read the page below as a record of what was declared, not as a register of what is held.

SPACs declared

every position whose latest statement stands — the record

Re-affirmed in 12 months

filed inside 365 days — what a reader means by "owns"

Still live

positions in SPACs still searching or in an announced deal

Median stake

8.0%

no percentage stated on the cover pages

1 activist (13D)

Positions

one row per SPAC — every figure read from the accession in the Source column

1 of 1 shown · 1 position has not been amended in over a year

	SPAC			Voting	Dispositive			Source
NUVB	Panacea Acquisition Corp6 reporting persons on this schedule	8.0%	26,600,496	0 / 26,600,496	0 / 26,600,496	Closed (deSPAC)	Sep 10, 2024Stale	SC 13D · may seek to influence control0001104659-24-098630

Reporting persons on this filer's schedules

one filer, several names — collapsed once, shown in full

A joint Schedule 13 names every person who beneficially owns the shares — the management company, the funds it advises, the general partner and often the individual who controls all three. They report the same shares. Counting them separately would publish this filer’s footprint two or three times over, so they are counted once, under CIK 0001736814. This filer has named 6 of them across the schedules in the table above:

Decheng Anbio
Decheng Capital China Life Sciences USD Fund III
Decheng Capital Global Healthcare Fund (Master)
Decheng Capital Global Healthcare GP
Decheng Capital Management III (Cayman)
Xiangmin Cui

Appears alongside

other filers with a current declared position in the same SPACs

Co-occurrence in the disclosure record, and nothing more. It is not evidence of a group, an agreement or acting in concert — filers who act as a group say so on the cover page and file a 13D. Two arbitrage funds above 5% in the same shell is the ordinary shape of this market. The second number restricts both sides to statements filed in the last 12 months, because a 2021 stake beside a 2026 one is two facts about two different years.

Every percentage above is the one printed on the cover page of the filing cited beside it — a percentage of the shares outstanding on that date. A SPAC’s float collapses at each redemption, so two of these percentages are percentages of two different companies and they do not add. Rows are one per SPAC: where a joint schedule names several reporting persons, the largest single figure is shown rather than their sum, because a manager and the funds it advises beneficially own the same shares. Nothing on this page is derived from a 13F, a vendor holdings file or a press release. See how this is built.